Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00504543
Status:
COMPLETED
Last Update Posted:
2016-11-18
First Post:
2007-07-19
Brief Title:
Efficacy Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 12 Month Open-label Randomized Multicenter Sequential Cohort-group Dose Finding Study to Evaluate the Efficacy Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus Basiliximab and Corticosteroids in de Novo Adult Renal Transplant Recipients
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AEB071
Brief Summary:
This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free calcineurin inhibitor regimen in renal transplant recipients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None